Medindia LOGIN REGISTER
Medindia
Advertisement

New York Medicaid Program Establishes Coverage for Trofile(TM)

Tuesday, April 8, 2008 General News
Advertisement
SOUTH SAN FRANCISCO, Calif., April 8, 2008 Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that New YorkMedicaid has established coverage and reimbursement for Monogram's TrofileAssay, a diagnostic used to determine patient candidacy for Pfizer's new HIVanti-viral medication Selzentry(TM) (maraviroc).
Advertisement

Initiated in 1989 to ensure early identification and access to qualitycare for New Yorkers who can't afford medical care, the HIV Primary CareMedicaid Program revised its reimbursement structure in response to advancesin HIV treatment and testing technology. With the establishment of coverage bythe medicaid program, coverage will also be available from the New York ADAPprogram so that comprehensive coverage will now be available from all publicpayers in New York.
Advertisement

"New York remains the epicenter of the HIV/AIDS epidemic in the U.S.,"said Dennis deLeon, President of the Latino Commission on AIDS. "The state'scoverage and reimbursement of Trofile allows greater access to an advancedtreatment option for the most vulnerable of our population living with HIV."

"We are very pleased that New York Medicaid has established coverage forTrofile," said Bill Welch, Monogram Chief Commercial Officer. "Now the medicalpublic assistance programs for the states with the largest numbers ofresidents living HIV/AIDS -- namely California, Texas, Florida and New York --recognize the need and provide reimbursement for accurate tropism testing."

Trofile is now a covered benefit among 25 state Medicaid programs,including California, Florida, Illinois, Maryland, Massachusetts, Michigan,New Jersey, Ohio, Texas and Wisconsin. In addition, Trofile is a coveredbenefit by Medicare, the Veteran's Administration, the Corrections and PrisonSystems and Department of Indian Affairs, as well as with a number of privatepayers.

Monogram introduced Trofile in August 2007, upon FDA approval of Pfizer'sSelzentry(TM) (maraviroc), and since then, almost 6,000 tests have beenperformed for patients throughout the U.S. In January 2008 DHHS Guidelines forUse of Antiretroviral Agents in HIV - 1 infected Adults & Adolescentsrecommend the use of the Trofile assay whenever the use of a CCR5 inhibitor isbeing considered as well as to be considered for patients who exhibitvirologic failure on a CCR5 inhibition.

About Monogram

Monogram is advancing individualized medicine by discovering, developingand marketing innovative products to guide and improve treatment of seriousinfectious diseases and cancer. The Company's products are designed to helpdoctors optimize treatment regimens for their patients that lead to betteroutcomes and reduced costs. The Company's technology is also being used bynumerous biopharmaceutical companies to develop new and improved antiviraltherapeutics and vaccines as well as targeted cancer therapeutics. Moreinformation about the Company and its technology can be found on its web siteat www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. Theseforward-looking statements include references to the demand for our TrofileAssay, the potential use of our Trofile Assay for patient selection formaraviroc, the size and timing of clinical trials utilizing our products, theoutlook for maraviroc and our Trofile Assay, the number of patients each yearin the U.S. who potentially could be candidates for new classes of HIV drugssuch as maraviroc, expected protection provided by patents, possibleregulation of Trofile and our other products by the FDA, and activitiesexpected to occur in connection with the Pfizer collaboration. These forward-looking statements are subject to risks and uncertainties and other factors,which may cause actual results to differ materially from the anticipatedresults or other expectations expressed in such forward-looking statements.These risks and u
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close